8-K: Predictive Oncology Faces Nasdaq Delisting Threat Over Stockholders' Equity Deficiency

Predictive Oncology Inc. has received a delisting notice from Nasdaq due to its failure to meet the minimum $2.5 million stockholders' equity requirement, though it has appealed the decision.

Summary

• Predictive Oncology Inc. received a delisting notice from The Nasdaq Stock Market LLC on June 9, 2025.
• The notice states the company failed to regain compliance with the minimum $2,500,000 stockholders' equity requirement for continued listing on The Nasdaq Capital Market (Nasdaq Listing Rule 5550(b)(1)).
• The company was unable to complete its previously submitted plan of compliance within the 180-day extension period provided by Nasdaq.
• Unless an appeal was requested by June 16, 2025, trading of the company's common stock would be suspended at the opening of business on June 18, 2025, and a Form 25-NSE would be filed with the SEC, removing the securities from listing and registration.
• Predictive Oncology has submitted a hearing request to Nasdaq's Hearings Panel to appeal the Staff's determination, which temporarily stays the suspension of its securities and the filing of the Form 25-NSE pending the Panel's decision.
• There is no assurance that the Company's request to continue listing will be accepted or that, if accepted, the Company will be able to maintain compliance with requirements for its continued listing on The Nasdaq Capital Market.

Sentiment

Score: 3

Explanation: The company faces a significant threat of delisting from Nasdaq due to non-compliance with financial requirements, indicating severe financial distress and uncertainty, despite the temporary stay from the appeal.

Positives

• The Company has submitted a hearing request to Nasdaq's Hearings Panel, which temporarily stays the suspension of its securities and the filing of Form 25-NSE pending the Panel's decision.

Negatives

• Predictive Oncology Inc. failed to regain compliance with Nasdaq's minimum $2,500,000 stockholders' equity requirement.
• The company received a delisting notice from Nasdaq, indicating a determination to delist its securities.
• The company was unable to complete its previously submitted plan of compliance within the 180-day extension period.
• There is no assurance that the Company's request to continue listing will be accepted by the Nasdaq Hearings Panel.
• Even if the appeal is accepted, there is no assurance the Company will be able to maintain compliance with continued listing requirements.

Risks

• Risk of delisting from The Nasdaq Capital Market if the appeal to the Hearings Panel is unsuccessful or if the company fails to regain compliance with listing standards.
• Uncertainty regarding the outcome of the appeal process and the Panel's decision.
• Potential loss of liquidity and investor confidence if the company's securities are delisted.
• Inability to meet future listing requirements even if a temporary exception is granted by the Panel.

Future Outlook

The company plans to continue evaluating all available options to regain compliance with Nasdaq's listing requirements. However, there is no assurance that its appeal to the Nasdaq Hearings Panel will be accepted or that it will be able to maintain compliance if an exception is granted.

Management Comments

• The Company will continue to evaluate all available options to regain compliance with the listing requirements.

Industry Context

This event is specific to Predictive Oncology Inc.'s compliance with Nasdaq's listing rules, which are standard for publicly traded companies. Failure to meet such requirements can lead to delisting, impacting a company's ability to raise capital and its stock's liquidity, a common challenge for smaller or struggling public companies across various industries.

Stakeholder Impact

• Shareholders face significant risk of loss of liquidity and potential decrease in share value if the company is delisted from Nasdaq.
• Delisting could reduce the company's visibility and attractiveness to new investors, potentially hindering future capital raising efforts.

Next Steps

• Nasdaq's Hearings Panel will review the Company's appeal regarding the delisting determination.
• The Panel will make a decision regarding the Company's continued listing on The Nasdaq Capital Market.
• The Company will continue to evaluate all available options to regain compliance with Nasdaq's listing requirements.

Key Dates

Recommendation

Keywords

Predictive Oncology, POAI, Nasdaq, delisting, stockholders equity, listing requirements, 8-K filing, corporate governance, financial compliance, publicly traded